Advertisement

Topics

FDA expands approval of new treatment for adult patients with chronic graft versus host disease

08:59 EDT 2 Aug 2017 | News-Medical.net

The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments.

Original Article: FDA expands approval of new treatment for adult patients with chronic graft versus host disease

NEXT ARTICLE

More From BioPortfolio on "FDA expands approval of new treatment for adult patients with chronic graft versus host disease"

Quick Search
Advertisement